Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Collaborating at the Leadership Level: Q&A with Lisa Fitzgerald, MD, & George Tsokos, MD

Carina Stanton  |  May 1, 2020

Q: What types of appointments are you conducting, and what are patients’ chief concerns regarding COVID-19’s potential risks and symptoms?
Dr. Fitzgerald: For the most part, we are scheduling patients in telemedicine slots in the same way as if they were in the office. In other words, we are trying our best to be very productive. Our patients are very appreciative of the chance to review their health situation in this way.

Many of our patients are very anxious about COVID-19, and some have had family members who have tested positive for COVID-19. So there have been a lot of questions surrounding these issues. Especially in the beginning, many patients had questions about whether to continue their immunosuppressive medications [even without any infectious symptoms], whether it be [disease-modifying anti-rheumatic drugs] or biologics. We settled these questions and advised the vast majority of patients to continue their medications as usual.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

We find that many patients are misinformed about the symptoms of COVID-19, thinking a runny nose and a cough related to allergies represents possible disease. And we definitely tell them they must also have a fever to have the infection. We have referred appropriate patients for COVID-19 testing. We do have patients who are healthcare workers who have questions about whether they should work near COVID-19 patients. We address this on a case-by-case basis.

Q: How is the pandemic affecting you and your staff personally?
Dr. Fitzgerald: Our staff has been phenomenal, and we are very fortunate to have a highly experienced and talented manager, Pat Harris, who keeps everyone sane and focused. Three of our six fellows have been deployed for [intensive care unit] or medical floor duty, and we are extremely proud of them and their work. Our remaining three fellows are helping with the extra consults and telemedicine visits. We are grateful to all our fellows for their excellent work and care of our patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

We are concerned, worried and saddened by the suffering and the loss of life COVID-19 is causing in our country and the world. Our goal as physicians is to stay focused so that we may take care of our patients, our families and ourselves, and convey a sense of hope that things will be better.

Dr. Tsokos: People are concerned about their health and the health of their families. We have found it very important to be in continuous touch with all members of our division to discuss updates, progress, solutions to emerging problems and to adjust fast to a situation that changes with the speed of light. We adapt to telemedicine by phone and video, and we adjust to our colleagues being enlisted to provide help to the hospital as it becomes overloaded with COVID-19 patients. It is a difficult time, but we are resilient, and we will overcome.

Page: 1 2 3 | Single Page
Share: 

Filed under:Professional Topics Tagged with:collaborationcoronavirusCOVID-19Leadership

Related Articles

    Rheum After 5: Dr. George Tsokos Shares His Love & Friendship with a Cat

    October 19, 2020

    George C. Tsokos, MD, professor of medicine at Harvard Medical School and chief of the Division of Rheumatology, Beth Israel Deaconess Medical Center, both in Boston, doesn’t recall the moment he first became infatuated with Little, a 12-year-old Siamese cat. Dr. Tsokos doesn’t even own Little. Not that anyone can truly own any living creature….

    The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

    March 17, 2020

    In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

    Practicing Telemedicine Raises Legal Considerations for Rheumatologists

    July 12, 2016

    With the evolution and advancement of technology, it was only a matter of time before such changes affected the medical industry. Although the concept of telemedicine dates back more than 50 years, emphasis on cost-effective quality healthcare coupled with technological advancements has caused a resurgence of telemedicine in recent years. What constitutes telemedicine largely depends…

    Protein Phosphatase 2A and Regulatory T Cell Function Researched

    June 13, 2016

    The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences